Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2001

View Archived Issues

Researchers reveal crystal structure of antibody against HIV

Testosterone protects human primary neurons from apoptosis

Hormone replacement therapy has osteoprotective effects in elderly women

Ultracet combination analgesic approved by FDA for acute pain relief

Seattle Genetics initiates phase II trial with SGN-15

Chrysalis reports positive trends from pilot Chrysalin clinical trial for diabetic ulcers

Immunex and Wyeth-Ayerst to commence longitudinal rheumatoid arthritis study

Novogen to initiate clinical trial of oral phenoxodiol in advanced prostate cancer

Ivax announces encouraging phase I results of BNP-166 as treatment of Crohn's disease

Biomira and Merck KGaA to meet with FDA regarding Theratope vaccine

Visudyne approved for additional ocular conditions in the U.S.

Enrollment for study of Zadaxin in hepatitis B in Japan completed

Lilly and Isis establish antisense strategic alliance

Study of Cytran's IM-862 in ovarian cancer begins at Magee-Womens Hospital

Revised Remicade label strengthens warnings about risk of infections

Schering-Plough highlights next-generation farnesyl protein transferase inhibitors at ACS meeting

Patient dosing completed in phase II study of Alista for treatment of FSD

Selective beta3-adrenoceptor agonists designed at Asahi Kasei

Sterix patents novel steroid sulfatase inhibitors

Potent inhibitors of IL-5 gene expression identified at Abbott

Jenapharm reports compounds with affinity for progesterone and/or glucocorticoid receptors

New series of inhibitors of TNF production may be useful as immunosuppressants

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.